Alefacept treatment for refractory chronic extensive GVHD

[1]  M. Röcken,et al.  Immunopathogenesis and role of T cells in psoriasis. , 2007, Clinics in dermatology.

[2]  A. Svejgaard,et al.  Changes in circulating lymphocyte subpopulations following administration of the leucocyte function‐associated antigen‐3 (LFA‐3)/IgG1 fusion protein alefacept , 2007, Clinical and experimental immunology.

[3]  K. Scott Baker,et al.  The management and outcome of chronic graft‐versus‐host disease , 2007, British journal of haematology.

[4]  K. Wittkowski,et al.  Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis , 2007, Journal of Translational Medicine.

[5]  K. Gordon,et al.  Alefacept in corticosteroid refractory graft versus host disease: Early results indicate promising activity , 2007, The Journal of dermatological treatment.

[6]  P. Lachenbruch,et al.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  P. Tsirigotis,et al.  Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report , 2005, Bone Marrow Transplantation.

[8]  K. Wittkowski,et al.  Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Finke,et al.  Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies , 2004, Annals of Hematology.

[10]  M. Lebwohl,et al.  An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. , 2003, Archives of dermatology.

[11]  D. Alexander,et al.  Alefacept selectively promotes NK cell‐mediated deletion of CD45R0+ human T cells , 2003, European journal of immunology.

[12]  K. Cleary,et al.  Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. , 2001, Blood.

[13]  D. Paniagua,et al.  Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Krueger,et al.  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. , 2001, The New England journal of medicine.

[15]  S. Singhal,et al.  Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. , 2000, Blood.

[16]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.

[17]  P. Ljungman,et al.  Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis , 1998, Bone Marrow Transplantation.

[18]  H. Deeg,et al.  Long-term outcome after marrow transplantation for severe aplastic anemia. , 1998, Blood.

[19]  A. Oppenheim,et al.  Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. , 1996, Bone marrow transplantation.

[20]  A. Barrett,et al.  Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia Using Sibling and Volunteer Unrelated Donors: A Comparison of Complications in the First 2 Years , 1993, Annals of Internal Medicine.

[21]  R. Storb,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. , 1990, Blood.

[22]  A. Rimm,et al.  Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. , 1990, Blood.

[23]  D. Weisdorf,et al.  Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. , 1990, Blood.

[24]  Y. Nakamura,et al.  Variable number of tandem repeat (VNTR) markers for human gene mapping. , 1987, Science.

[25]  S. Pavletic,et al.  Chronic Graft versus Host Disease: Interdisciplinary Management: Contents , 2009 .

[26]  M. Heffernan,et al.  Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). , 2007, Journal of the American Academy of Dermatology.

[27]  L. Chatenoud.  Monoclonal antibody-based strategies in autoimmunity and transplantation. , 2005, Methods in molecular medicine.

[28]  D. Weisdorf,et al.  Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. , 1994, Bone marrow transplantation.